NAA Services for Anti-p90

During the past decade, autoantibodies have drawn much attention because they can direct against tumor-associated antigens which have been shown to be relevant tumor markers. The application of NAAs (natural autoantibodies) in a variety of diseases offers potential possibilities for future clinical treatment. Creative Biolabs has the experience and high-end technologies in NAA research. We are able to provide a full range of anti-p90 marker services for gastric cancer diagnosis and therapeutic monitoring. Our professional team is optimized to help you get a milestone development in your NAA project.

Background of Anti-p90

Cancerous inhibitor of protein phosphatase 2A (CIP2A), originally named p90, localized to the cytoplasm in cultured cells and fetal mouse. Full-length cDNA encoding p90 was successfully isolated from a T24 expression library and comprised a sequence coding for a protein of 905 amino acids with predicted molecular mass of 102 kDa. CIP2A/p90 is a recently characterized endogenous inhibitor of the phosphatase activity of protein phosphatase 2A (PP2A). It can directly interact with the oncogenic transcription factor c-myc, inhibits PP2A activity towards c-myc serine 62 (S62), and thereby prevents c-myc proteolytic degradation. In multiple human solid tumor types, including gastric cancer and hepatocellular carcinoma, the expression of CIP2A/p90 is much higher in the tumor tissue than in the surrounding normal tissue which has emerged as a potential drug target for a range of different tumor types.

The Role of Anti-p90 in Gastric Cancer

Cancer is a complex and diverse set of diseases related to the unharnessed growth, enhanced survival, and invasion of cells. Gastric cancer (GC) is characterized by a growth of cancerous cells within the lining of the stomach. The high mortality of GC is mostly due to late diagnosis of the disease. Curative treatment of gastric cancer requires complete surgical removal of the neoplastic tissue, but even with curative intent, the 5-year survival is only about 20% - 30%. Therefore, new diagnostic markers and treatment modalities are needed. Overexpression of c-Myc (MYC), as determined by immunohistochemistry, is associated with poor survival among gastric cancer patients. In nontransformed cells, MYC is a very short-lived protein due to degradation by ubiquitin-mediated proteasome process. CIP2A/p90 promotes MYC protein stability by inhibiting PP2A-mediated dephosphorylation of MYC at serine 62. CIP2A/p90 immunopositivity was also shown to be associated with nuclear c-MYC positivity, aneuploidy and high S-phase fraction, which highlighted its role as a marker of aggressive tumor behavior. CIP2A and MYC appear to be regulated in a positive feedback loop, wherein they promote each other's expression and gastric cancer cell proliferation. CIP2A/p90 immunopositivity is a predictor of survival for some subgroups of gastric cancer patients, therefore, autoantibody to CIP2A/p90 may provide a potential novel marker for gastric cancer detection.

Mechanisms known to regulate CIP2A expression in human cancers. Fig.1 Schematic model of the CIP2A involvement in tumor growth. (Soofiyani, et al., 2017)

What We Can Do About NAA?

NAAs are self-reacting antibodies found in the serum. They are a key component for immune surveillance function. Aided by our well-established platforms and experienced scientists, we can provide comprehensive NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. In addition, a wide spectrum of NAA products is available for your choice.

Features of Our Services

Creative Biolabs can offer the largest and diversiform portfolio of NAA products and services. Our proven and optimized platforms can help you quickly get satisfactory results without repeated trials. We also provide custom services based on the requirements of the clients to meet the specific demand. If you have any special needs in NAA services or be interested in learning more about Creative Biolabs’ NAA services, please feel free to contact us for more details.

References:

  1. Soofiyani, S. R.; et al. The role of CIP2A in cancer: a review and update. Biomedicine & Pharmacotherapy. 2017, 96: 626-633.
  2. Anchit Khanna. Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. Int J Cancer. 2016, 138: 525-532.
For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry